Literature DB >> 26290183

Molecular characterization of extended-spectrum beta-lactamases (ESBLs) produced by clinical isolates of Acinetobacter baumannii in Saudi Arabia.

Essam J Alyamani1, Mohamed A Khiyami2, Rayan Y Booq3, Basel M Alnafjan4, Musaad A Altammami5, Fayez S Bahwerth6.   

Abstract

BACKGROUND: Acinetobacter baumannii is a common opportunistic pathogen that causes major nosocomial infections in hospitals. In this study, we hypothesized a high prevalence of A. baumanni ESBL (extended-spectrum beta-lactamase) among all collected isolates.
METHODS: A. baumannii isolates (n = 107) from ICU (Intensive care unit) of local hospitals in Makkah were phenotypically and genotypically characterized. The identity and antibiotic susceptibility of A. baumannii strains were determined using the Vitek-2 system. The identified ESBL producers were further analyzed by PCR and sequencing followed by MLST typing. bla TEM , bla SHV , and the bla CTX-M-group genes 1, 2, 8, 9, and 25 were investigated. Furthermore, bla OXA51-like and bla OXA23-like genes were also examined in the carbapenem-resistant A. baumannii isolates.
RESULTS: Our data indicated a high prevalence of A. baumannii ESBL producers among the collected strains. Of the 107 A. baumannii isolates, 94 % were found to be resistant to cefepime and ceftazidime, and aztreonam using the Vitek 2 system. The genes detected encoded TEM, OXA-51-like and OXA-23-like enzymes, and CTX-M-group proteins 1, 2, 8, 9, and 25. MLST typing identified eight sequence type (ST) groups. The most dominant STs were ST195 and ST557 and all of them belong to worldwide clonal complex (CC) 2.
CONCLUSIONS: This study has shown that there is a high prevalence of antimicrobial resistance in A. baumannii. The diversity of STs may suggest that new ESBL strains are constantly emerging. The molecular diversity of the ESBL genes in A. baumannii may have contributed to the increased antimicrobial resistance among all isolates.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26290183      PMCID: PMC4545919          DOI: 10.1186/s12941-015-0098-9

Source DB:  PubMed          Journal:  Ann Clin Microbiol Antimicrob        ISSN: 1476-0711            Impact factor:   3.944


Background

Acinetobacter baumannii is an opportunistic and rapidly emerging pathogen. It is an important agent of nosocomial infections worldwide, such as urinary tract infections, septicemia, pneumonia, burns, meningitis, and wound infections in hospitals, due to its remarkable propensity to rapidly acquire resistance determinants to a wide range of antibacterial agents [1-4]. Many studies have documented high rates of multidrug-resistance (MDR) in A. baumannii [4-6]. The development of resistance to the third-generation cephalosporins was a major breakthrough in the fight against MDR strains. However, due to the frequent use of these agents, new plasmids encoding β-lactamase capable of hydrolyzing extended-spectrum cephalosporins were first reported in 1983 [7, 8]. These extended-spectrum β-lactamases (ESBLs) are mutant, plasmid-mediated, and produced by gram negative bacilli that mediate resistance to penicillin, cephalosporins, and monobactams [9]. These ESBLs are commonly recognized in Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii and are found worldwide [10]. The majority of ESBLs are members of either the TEM, SHV, or CTX-M (class A) families based on the Ambler molecular classification of β-lactamase genes [11, 12]. One of the major genes of ESBL family is the CTX-M, which is divided into five phylogenetic groups based on amino acid sequence identity: the CTX-M-1 group, the CTX-M-2 group, the CTX-M-8 group, the CTX-M-9 group, and the CTX-M-25 group. The presence and prevalence of these different groups are variable depending on the geographical locale [13, 14]. In Saudi Arabia, the high prevalence of ESBL A. baumannii was reported in several studies [15-17]. The PCR technology is widely used technique to screen for ESBL in modern hospitals. A specific multiplex PCR assay has been optimized to screen for multiple ESBL genes to facilitate and monitoring the spread and emergence of ESBL-producing bacteria [18]. The epidemiologic characterization of A. baumannii by multilocus sequence typing (MLST) is a highly used method and has been applied successfully [19]. With reports on the high prevalence of ESBL production in members of A. baumannii globally and a paucity of information specifically regarding the emergence of ESBL A. baumannii in major Saudi general hospitals in Makkah, this study reports the analysis of the antibiotic susceptibility profiles and molecular characterization of 107 A. baumannii ESBL producers isolated from ICU ward based on the phenotypic and genotypic approach. Understanding the molecular nature of the spread of A. baumannii in local hospitals is important, especially in hospitals that admit thousands of local and foreign people during their holy journey to Makkah. This work may enhance our understanding of the extent of the epidemiologic re-emergence of this bacterium. The genes that were investigated from A. baumannii isolates by PCR were bla, bla, and the blagroup genes 1, 2, 8, 9, and 25. Furthermore, bla and bla enzymes were examined in carbapenem-resistant A. baumannii. This work may partially contribute to the global effort to map the molecular signature of A. baumannii.

Methods

Study design

A total of 107 bacterial isolates were collected from different ICU patients from clinical labs at local general hospitals in Makkah during 2 years from 2012 to 2014. Samples were subjected to a conventional microbiology analysis, phenotyping, and genotyping characterizations at the national center for biotechnology, KACST. The nature of the samples were blood, and skin wound infections predominantly.

Species identification and antimicrobials susceptibilities

Bacterial identities were confirmed using the Vitek 2 system (GN ID Card, bioMérieux, Craponne, France) and PCR. Antibiotic susceptibility testing was conducted according to the manufacturer’s recommendations (gram negative antimicrobial susceptibility testing (AST) cards, bioMérieux, Craponne, France). The extraction of genomic DNA was performed using QIAGEN kits (QIAamp DNA Mini Kit, cat# 69506, QIAGen, Valencia, CA, USA) according to the manufacturer’s recommendations and or the MagNA Pure LC DNA Isolation Kit III Bacteria, Fungi (Roche, Basel, Switzerland). The results of Vitek ESBL susceptibility test were reported according to the CLSI criteria. Quality-control bacterial strains (E. coli ATCC 35218 and Pseudomonas aeruginosa ATCC 27853) were used in all tests.

Detection of ESBL and carbapenem genes by PCR

All of the positive ESBL isolates according to phenotypic assays (n = 100) were further confirmed by PCR and sequencing. The genes investigated in this study were the bla, bla, and blagroup genes 1, 2, 8, 9, and 25. Furthermore, bla and bla enzymes were tested for carbapenem-resistant A. baumannii. The gDNA was extracted using a QIAamp Genomic DNA kit (QIAGEN, Venlo, Netherlands) and used for PCR directly, or overnight cultures were boiled at 95 °C for 10 min to produce a bacterial gDNA/plasmid lysate that was diluted 1:10 with ddH2O before it was used for PCR. PCR amplification was performed with either 1 µl of pure gDNA or 10 µl of gDNA/plasmid lysate as a template. Final reactions of 25 μl of illustra PuReTaq Ready-To-Go PCR beads (GE Health Biosciences, USA) were used in the PCR reaction according to the manufacturer’s recommendations. The reactions were set up as follows: 10–22 μl of nuclease-free water (Promega) depending on the DNA templates being used; 2 µl of 10 pmol of each bla, bla, and blagroup genes 1, 2, 8, 9, and 25; bla and bla forward and reverse primers (Eurofins MWG Operon, Germany); and 1–10 µl of DNA template or bacterial lysate were used (Table 1) [18]. The cycling conditions of the PCR are illustrated in Table 1. All of the amplicons were size fractionated using 1 % agarose gel electrophoresis and visualized under ultraviolet illumination using the Gel Doc EZ system (Bio-Rad, Hercules, CA, USA).
Table 1

Primers for the rapid characterization of A. baumannii by multiplex PCR

No.blaOXA-like enzymes of A. baumannii Amplification conditions
 1blaOXA-51 F5′-TAA TGC TTT GAT CGG CCT TG353 bpInitial denaturation at 94 °C for 5 min, followed by 30 cycles of 94 °C for 25 s, 52 °C for 40 s and 72 °C for 50 s, and a final elongation at 72 °C for 6 min
 2blaOXA-51R5′-TGG ATT GCA CTT CAT CTT GG
 3blaOXA-23-F5′-GAT CGG ATT GGA GAA CCA GA501 bp
 4blaOXA-23-R5′-ATT TCT GAC CGC ATT TCC AT
blaCTX-M genes
 7Group 1-F5′-AAA AAT CAC TGC GCC AGT TC415 bpInitial denaturation at 94 °C for 5 min, followed by 30 cycles of 94 °C for 25 s, 52 °C for 40 s and 72 °C for 50 s, and a final elongation at 72 °C for 6 min
 8Group 1-R5′-AGC TTA TTC ATC GCC ACG TT
 9Group 2-F5′- CGA CGC TAC CCC TGC TAT T552 bp
 10Group 2-R5′-CCA GCG TCA GAT TTT TCA GG
 11Group 9-F5′-CAA AGA GAG TGC AAC GGATG205 bp
 12Group 9-R5′-ATT GGA AAG CGT TCA TCA CC
 13Group 8F5′-TCG CGT TAA GCG GAT GAT GC666 bp
 14Group 8R5′-AAC CCA CGA TGT GGG TAG C
 15Group 25F5′-GCA CGA TGA CAT TCG GG327 bp
 16Group 25R5′-AAC CCA CGA TGT GGG TAG C
 1TEM-F5′-CATTTCCGTGTCGCCCTTATTC800 bpInitial denaturation at 94 °C for 10 min, followed by 30 cycles at 94 °C for 40 s, 60 °C for 40 s, and 72 °C for 1 min, and a final elongation step at 72 °C for 7 min
 2TEM-R5′-CGTTCATCCATAGTTGCCTGAC
 3SHV-F5′-AGCCGCTTGAGCAAATTAAAC713 bp
 4SHV-R5′-ATCCCGCAGATAAATCACCAC
 116S rRNA 8F5′-GCG GAT CCG CGG CCG CTG CAG AGT TTG ATC CTG GCT CAG797 bpInitial denaturation at 94 °C for 5 min, followed by 35 cycles at 94 °C for 60 s, 55 °C for 30 s, and 72 °C for 60 s, and a final elongation step at 72 °C for 7 min
 216S rRNA 805R5′-GCG GAT CCG CGG CCG CGG ACT ACC AGG GTA TCT AAT
Primers for the rapid characterization of A. baumannii by multiplex PCR

Amplification and sequencing of the 16S rRNA gene

Amplification and sequencing of 16S rRNA were performed to confirm the identity of A. baumannii used in this study [20]. In the PCR amplification, each reaction contained 25 μl of illustra PuReTaq Ready-To-Go PCR beads (GE Health Biosciences, USA). The reaction was set up as follows: 22 μl of nuclease-free water (Promega), 2 µl of 10 pmol of each forward and reverse primer (Eurofins MWG Operon, Germany) were used (Table 1) [18]. Exactly 1 μl of 100 ng/µl DNA template was added to the beads. The amplification conditions are highlighted in Table 1. The amplification products were subjected to gel electrophoresis in 1 % agarose followed by ethidium bromide staining and were visualized under ultraviolet illumination using the Gel Doc EZ system (Bio-Rad, Hercules, CA, USA). Sense and anti-sense strands of PCR amplicons were purified and sequenced in an ABI 3130 Genetic Analyzer (Life Technologies, Carlsbad, CA, USA) using ABI BigDye terminator cycle sequencing ready reaction kit chemistry according to the manufacturer’s recommendations. Following sequencing, the data were identified using a basic local alignment search tool BLAST-n (http://www.ncbi.nlm.nih.gov/BLAST) or RDP database [21]. The identification of A. baumannii using the 16S rRNA was unequivocal. Therefore, there was no need to use additional confirmatory targets such as rpoB and gyrB genes [22].

Multilocus sequence typing (MLST)

The Acinetobacter baumannii complex MLST typing was performed by utilizing seven house-keeping genes: Citrate synthase (gltA), DNA gyrase subunit B (gyrB), Glucose dehydrogenase B (gdhB), Homologous recombination factor (recA), 60-kDa chaperonin (cpn60), Glucose-6-phosphate isomerase (gpi), RNA polymerase sigma factor (rpoD). The primers used for amplification and sequencing are illustrated in Table 2 [19]. The PCR amplifications were completed in a MasterCycler nexus (Eppendorf, Hamburg, Germany) with the following conditions: 35 cycles of initial denaturation at 94 °C for 5 min, followed by 35 cycles of denaturation at 94 °C for 1 min, annealing at 55 °C for 1 min, and extension at 72 °C for 2 min and 4 min final extension at 72 °C. The PCR products were directly verified by 1 % agarose gel electrophoresis before they were purified from the reaction mixture for sequencing. Bidirectional sequencing was performed for each isolate. Different allele sequences were assigned for each locus with an arbitrary allele number for identification. Each bacterial isolate was characterized by a pattern of numbers defining its sequence type (ST). The sequences of the seven housekeeping genes were analyzed by using an A. baumannii database (http://pubmlst.org/abaumannii/) [23]. The allelic profile similarities were produced by BioNumerics version (7) created by Applied Maths NV. Available from (http://www.applied-maths.com).
Table 2

Primers used in PCR to amplify the seven housekeeping genes in A. baumannii isolates

No.LocusPrimerSequencesAmplicon size (bp)Usage
1 gltA Citrato F1AAT TTA CAG TGG CAC ATT AGG TCC C722Amp/seq
Citrato R12GCA GAG ATA CCA GCA GAG ATA CAC GAmp/seq
2 gyrB gyrB_FTGA AGG CGG CTT ATC TGA GT594Amp/seq
gyrB_RGCT GGG TCT TTT TCC TGA CAAmp/seq
3 gdhB GDHB 1FGCT ACT TTT ATG CAA CAG AGC C774Amp
GDH SEC FACC ACA TGC TTT GTT ATGSeq
GDHB 775RGTT GAG TTG GCG TAT GTT GTG CAmp
GDH SEC RGTT GGC GTA TGT TGT GCSeq
4 recA RA1CCT GAA TCT TCY GGT AAA AC425Amp/seq
RA2GTT TCT GGG CTG CCA AAC ATT ACAmp/seq
5 cpn60 cpn60_FGGT GCT CAA CTT GTT CGT GA640Amp/seq
cpn60_RCAC CGA AAC CAG GAG CTT TAAmp/seq
6 gpi gpi_FGAA ATT TCC GGA GCT CAC AA456Amp/seq
gpi_RTCA GGA GCA ATA CCC CAC TCAmp/seq
7 rpoD rpoD-FACC CGT GAA GGT GAA ATC AG672Amp/seq
rpoD-RTTC AGC TGG AGC TTT AGC AATAmp/seq
Primers used in PCR to amplify the seven housekeeping genes in A. baumannii isolates

Ethics statement

Ethical approval and consent were not required for this project because no human nor animal subjects were used.

Results

Antimicrobial susceptibility testing and screening for ESBL

In this study, 94 % (100/107) of A. baumannii were MDR. Among the 107 isolates of A. baumannii tested, one hundred isolates were confirmed as ESBL producers by phenotypic and genotypic assays, four isolates were susceptible to the third generation cephalosporins (Figs. 1, 2) and three isolates were not confirmed as A. baumannii by 16S rRNA PCR. The ESBL A. baumannii were recovered from different clinical specimens, blood, and skin wound infections predominantly. The susceptibility data of the ESBL-producing A. baumannii showed that 94 % of the 107 isolates resistant to the panel of the VITEK 2 gram negative Susceptibility Card, whereas 4 % were sensitive isolates based on CLSI criteria.
Fig. 1

Cephalosporin susceptibility pattern by A. baumannii isolates. Among the 107 isolates of A. baumannii tested, 100 isolates (94 %) were confirmed as ESBL producers by phenotypic assay

Fig. 2

The overall distribution of ESBL and carbapenemase genes detected in A. baumannii isolates

Cephalosporin susceptibility pattern by A. baumannii isolates. Among the 107 isolates of A. baumannii tested, 100 isolates (94 %) were confirmed as ESBL producers by phenotypic assay The overall distribution of ESBL and carbapenemase genes detected in A. baumannii isolates

16S rRNA identification and the detection of ESBL and carbapenemase genes

The 16S rRNA sequencing of all isolates (n = 107) generated a high score (≥97 % in total) of A. baumannii identity using the BLAST and Ribosomal Database Project (http://rdp.cme.msu.edu/) [21, 24]. To determine the extent of genotypic diversity among the MDR A. baumannii, PCR and sequencing of bla, bla, and the blagroup genes 1, 2, 8, 9, and 25 and the bla, and bla genes were employed. All of the PCR-based ESBL-positive A. baumannii isolates (n = 100) were concordant with the phenotyping data. Of these isolates, seventy-one (71 %) harbored the blaTEM gene. None of them contained the blaSHV gene and eighty-one isolates (81 %) encoded blaCTX-M-group genes 1, 2, 8, 9, and 25. Finally, ninety-four (94 %) isolates carried the carbapenemase gene OXA51-like, and ninety-one isolates (91 %) contained OXA23-like (Table 3; Fig. 2). The sequencing analysis of all of the genes showed approximately 90 % sequence similarity to the submitted sequences that are related to the genes deposited in GenBank.
Table 3

Detection and ESBL genotyping of 107 Acinetobacter baumannii clinical isolates

PCR size501 bp353 bp713 bp800 bp327 bp205 bp666 bp552 bp415 bp
GeneCTX-M1CTX-M2CTX-M8CTX-M9CTX-M25TEMSHVOXA- 51-likeOXA-23-like
Positive isolates of 107 isolates97372106173010097
Percentage (%)817109491
Detection and ESBL genotyping of 107 Acinetobacter baumannii clinical isolates

Multilocus sequence typing analysis

MLST and sequence-based typing of ESBL and carbapenemase isolates were performed to analyze the genetic relationship of all of the isolates. The MLST anaylsis contains 97 isolates of 102. Five isolates were not typable due to low quality traces files and were not assigned STs but were included in the dendrogram. The MLST analysis allowed us to group the A. baumannii isolates into eight STs (Figs. 3, 4). MLST typing showed that the most dominant sequence type was ST195 (n = 69), followed by ST557 (n = 6), ST 208 (n = 4), ST499 (n = 2), ST218 (n = 2), ST231 (n = 1), ST222 (n = 1), and ST286 (n = 2). All of STs except ST 231 belonge to clonal complexity 2 (CC2) and lineage clone 2. The tree (Fig. 3) is based on the nucleotide sequence of at least 6 or 7 housekeeping genes. The analysis was based on data sets that include all STs in the Pasteur MLST databases of A. baumannii (http://pubmlst.org/abaumannii/).
Fig. 3

UPGMA (unweighted pair group method with arithmetic mean) dendrogram based on the catagorical coefficient applied to the allele IDs. All isolates with at least six loci amplified were included. The dendrogram was generated by BioNumerics 7 software. The ST numbers assigned for each isolate were generated by the Pasteur MLST scheme (http://pubmlst.org/abaumannii/). The tree is a rooted based on the nucleotide sequence of the six and seven housekeeping genes. The analysis was based on data sets that include all STs in the Pasteur MLST databases. The first clade consists of ST195, 208, 218 and 286; the second clade of ST231; the third clade of ST499; the fourth clade of ST 557; the fifth clade of ST222. The sixth and seventh clades have two nontypeable isolates due to low quality sequencing trace files

Fig. 4

Minimum spanning tree constructed based on the allele IDs

UPGMA (unweighted pair group method with arithmetic mean) dendrogram based on the catagorical coefficient applied to the allele IDs. All isolates with at least six loci amplified were included. The dendrogram was generated by BioNumerics 7 software. The ST numbers assigned for each isolate were generated by the Pasteur MLST scheme (http://pubmlst.org/abaumannii/). The tree is a rooted based on the nucleotide sequence of the six and seven housekeeping genes. The analysis was based on data sets that include all STs in the Pasteur MLST databases. The first clade consists of ST195, 208, 218 and 286; the second clade of ST231; the third clade of ST499; the fourth clade of ST 557; the fifth clade of ST222. The sixth and seventh clades have two nontypeable isolates due to low quality sequencing trace files Minimum spanning tree constructed based on the allele IDs

Discussion

In this study, we detected and characterized the phenotypic and genotypic nature of ESBL producers in A. baumannii, which were isolated from general hospitals in Makkah, Saudi Arabia. At least 107 A. baumannii isolates were characterized by the Vitek-2 system and PCR-sequencing followed by MLST typing. Our data indicated a high prevalence of A. baumannii ESBL producers among the collected isolates. A remarkable outcome of this study was the large number of antibiotic resistance genes found in these isolates. Ninety-four percent of A. baumannii isolates were found to have three major resistant determinants. We speculate that if more drug-resistant genes were screened, we would have found pan-resistant A. baumannii isolates. CTX-M β-lactamases produced by A.baumannii strains is plasmid-mediated hence the wide spread and long time survival in hospitals. The CTX-M gene activity conferring resistance to cefotaxime and ceftazidime. We detected CTX-M group 1, 2, 8, 9, 25 in our current study (81 %). The high rate of prevalence of CTX-M resistance in gram negative bacteria may be influenced by mobile genetic elements around these genes which include transposon, insertion sequences (IS) and integrons [25]. Consistent with our study, all gram negative CTX-M producing bacteria are often associated with other families of other β-lactamases resistance causing multi-drug resistance phenomena. The high prevalence rate around the world of CTX-M makes it a predominant drug resistant gene in gram negative bacteria [26]. We studied the dynamic spread of A.baumannii in our population by MLST. The discriminatory power of the MLST system is comparable to other techniques such as pulsed field gel electrophoresis (PFGE). Yet, MLST provides a quick and easy method to study the epidemiology of ESBL-producing bacteria and to monitor the international emergence of multidrug resistant bacteria. Consistent with other studies that used MLST in the epidemiologic characterization of clinically important bacterial pathogens such as A.baumannii, Streptococcus pneumoniae, Streptococcus pyogenes, Neisseria meningitidis, Campylobacter jejuni, Staphylococcus aureus, Enterococcus faecium, Haemophilus influenza, and Vibriocholera, our study has detected different allelic diversity (STs) which belongs to clonal complex (CC)2 which is globally distributed in Europe, Asia, Africa, Australia, USA, South America [19, 27–29]. The drug of choice to treat nosocomial infection caused by A.baumannii is the carbapenems. However, there is an increasing rate of carbapenem-resistant A.baumannii around the world caused by OXA23-like enzume or OXA51-like enzyme acitivies [30]. The first OXA23-like enzyme with carbapenem-activity to A. baumannii was isolated and characterized in Scotland in 1985. This drug-resistant determinant is encoded by the plasmid therefore it is transferable [31]. This may explain the high prevalence of carbapenemase-producing A. baumannii in hospitals around the world. The other gene cluster in the OXA family is the blaOXA-51-like gene which is chromosomally encoded and naturally occurs in A. baumannii. The functional product of this gene delivers carbapenemase resistance to meropenem and imipenem; its role in carbapenem resistance may be influenced by the presence of ISAba1. PCR mapping studies have found that the absence of this sequence upstream of blaOXA-51-like gene may contribute to a minimal effect on carbapenem susceptibility [32-36]. A recent study in the Gulf Countries Council (GCC) [37], namely, Saudi Arabia, the United Arab Emirates, Oman, Qatar, Bahrain, and Kuwait, suggested a high prevalence of carbapenemase resistance in A. baumannii, Escherichia coli and Klebsiella pneumonia.A. baumannii (n = 117) was studied as clusters in seven different sequence types: ST195, ST208, ST229, ST436, ST450, ST452 and ST499. Three of these sequences were identified in our study, including ST195, ST499, and ST208, which may suggest the circulation of these three STs in GCC countries [17, 37]. The circulation of the STs within GCC may be due to the closeness of these countries to each other. Recent reports have been accumulating from Saudi Arabia due to the wide and rapid spread of carbapenem-resistant gram negative bacteria isolated from local hospitals specially during high season [38-40]. The high level of detection of ESBL and carbapenemase resistance among local isolates may suggest an increasing incidence rate of infection with ESBL-producing A. baumannii. Such high rates of ESBL-producing bacteria may impose a burden on routine clinical practice, especially for patients with chronic diseases and immunocompromised patients. Although national surveillance data are lacking, outbreaks of infection due to ESBL-producing A. baumannii have been reported by many hospitals within the Kingdom of Saudi Arabia. The true prevalence of ESBL producers is not known and is likely underestimated because of the difficulties encountered in their detection by most local hospitals. However, it is clear that ESBL-producing bacteria are distributed worldwide and their prevalence is increasing [2, 6, 41, 42]. Therefore, periodic screening of ESBL-producing A. baumannii during the high hospital visitation season is recommended in all local hospitals to establish national surveillance data archives of the level of spread of ESBL producers.

Conclusions

In this study, we randomly surveyed and characterized ESBL-producing A. baumannii from ICU of local hospitals in Makkah city, Saudi Arabia. Our data indicated a high prevalence of A. baumannii ESBL producers among the collected isolates. Based on MLST typing, we have evidence of eight STs groups in our isolates. The epidemiologic diversity of these isolates may suggest that new ESBL strains are constantly emerging. The molecular diversity of the ESBL genes in A. baumannii may have contributed to the increased antimicrobial resistance among all isolates. Therefore, periodic screening of ESBL-producing A. baumannii during the high hospital visitation season is recommended in all local hospitals.
  40 in total

1.  Evaluation of a DNA microarray (Check-MDR CT102) for rapid detection of TEM, SHV, and CTX-M extended-spectrum β-lactamases and of KPC, OXA-48, VIM, IMP, and NDM-1 carbapenemases.

Authors:  Thierry Naas; Gaelle Cuzon; Pierre Bogaerts; Youri Glupczynski; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2011-02-16       Impact factor: 5.948

Review 2.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

3.  Comparison of rpoB gene sequencing, 16S rRNA gene sequencing, gyrB multiplex PCR, and the VITEK2 system for identification of Acinetobacter clinical isolates.

Authors:  Min Jung Lee; Sook Jin Jang; Xue Min Li; Geon Park; Joong-Ki Kook; Min Jung Kim; Young-Hyo Chang; Jong Hee Shin; Soo Hyun Kim; Dong-Min Kim; Seong-Ho Kang; Dae-Soo Moon
Journal:  Diagn Microbiol Infect Dis       Date:  2013-10-22       Impact factor: 2.803

4.  Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England.

Authors:  Juliana M Coelho; Jane F Turton; Mary E Kaufmann; Judith Glover; Neil Woodford; Marina Warner; Marie-France Palepou; Rachel Pike; Tyrone L Pitt; Bharat C Patel; David M Livermore
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

5.  Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina.

Authors:  S Brown; H K Young; S G B Amyes
Journal:  Clin Microbiol Infect       Date:  2005-01       Impact factor: 8.067

Review 6.  Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii.

Authors:  Nabil Karah; Arnfinn Sundsfjord; Kevin Towner; Ørjan Samuelsen
Journal:  Drug Resist Updat       Date:  2012-07-27       Impact factor: 18.500

7.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

8.  The Ribosomal Database Project (RDP).

Authors:  B L Maidak; G J Olsen; N Larsen; R Overbeek; M J McCaughey; C R Woese
Journal:  Nucleic Acids Res       Date:  1996-01-01       Impact factor: 16.971

9.  Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the Gulf cooperation council: dominance of OXA-48 and NDM producers.

Authors:  Hosam M Zowawi; Anna L Sartor; Hanan H Balkhy; Timothy R Walsh; Sameera M Al Johani; Reem Y AlJindan; Mubarak Alfaresi; Emad Ibrahim; Amina Al-Jardani; Seif Al-Abri; Jameela Al Salman; Ali A Dashti; Abdullah H Kutbi; Sanmarié Schlebusch; Hanna E Sidjabat; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

10.  BIGSdb: Scalable analysis of bacterial genome variation at the population level.

Authors:  Keith A Jolley; Martin C J Maiden
Journal:  BMC Bioinformatics       Date:  2010-12-10       Impact factor: 3.169

View more
  14 in total

1.  Molecular Surveillance of Multidrug-Resistant Acinetobacter baumannii.

Authors:  Aisha M AlAmri; Ameerah M AlQurayan; Tunny Sebastian; Amani M AlNimr
Journal:  Curr Microbiol       Date:  2019-12-12       Impact factor: 2.188

2.  The occurrence of ESBL-producing Escherichia coli carrying aminoglycoside resistance genes in urinary tract infections in Saudi Arabia.

Authors:  Essam J Alyamani; Anamil M Khiyami; Rayan Y Booq; Majed A Majrashi; Fayez S Bahwerth; Elena Rechkina
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-01-06       Impact factor: 3.944

3.  The emergence of a novel sequence type of MDR Acinetobacter baumannii from the intensive care unit of an Egyptian tertiary care hospital.

Authors:  Doaa Mohammad Ghaith; Mai Mahmoud Zafer; Mohamed Hamed Al-Agamy; Essam J Alyamani; Rayan Y Booq; Omar Almoazzamy
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-05-10       Impact factor: 3.944

4.  Occurrence of blaTEM and blaCTXM Genes and Biofilm-Forming Ability among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii in Yaoundé, Cameroon.

Authors:  Estelle Longla Madaha; Hortense Kamga Gonsu; Rhoda Nsen Bughe; Marie Christine Fonkoua; Collins Njie Ateba; Wilfred Fon Mbacham
Journal:  Microorganisms       Date:  2020-05-11

5.  The Frequency of Antibiotic Resistance and ESBLs Among Clinically Acinetobacter baumannii Strains Isolated from Patients in a Major Hospital in Tehran, Iran.

Authors:  Reza Ranjbar; Sajjad S Tolon; Shahin Zayeri; Mehrdad Sami
Journal:  Open Microbiol J       Date:  2018-07-31

6.  Characterization of phenotypic and genotypic traits of carbapenem-resistant Acinetobacter baumannii clinical isolates recovered from a tertiary care hospital in Taif, Saudi Arabia.

Authors:  Mohamed F El-Badawy; Sayed F Abdelwahab; Saleh A Alghamdi; Mohamed M Shohayeb
Journal:  Infect Drug Resist       Date:  2019-10-03       Impact factor: 4.003

Review 7.  Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii.

Authors:  Corneliu Ovidiu Vrancianu; Irina Gheorghe; Ilda Barbu Czobor; Mariana Carmen Chifiriuc
Journal:  Microorganisms       Date:  2020-06-21

8.  Appropriateness of empiric antimicrobial therapy with imipenem/colistin in severe septic patients: observational cohort study.

Authors:  Ahlem Trifi; Sami Abdellatif; Cyrine Abdennebi; Foued Daly; Rochdi Nasri; Yosr Touil; Salah Ben Lakhal
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-11-16       Impact factor: 3.944

Review 9.  Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach.

Authors:  Iman Dandachi; Amer Chaddad; Jason Hanna; Jessika Matta; Ziad Daoud
Journal:  Front Microbiol       Date:  2019-08-23       Impact factor: 5.640

10.  Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings.

Authors:  Mariana Neri Lucas Kurihara; Romário Oliveira de Sales; Késia Esther da Silva; Wirlaine Glauce Maciel; Simone Simionatto
Journal:  Rev Soc Bras Med Trop       Date:  2020-11-06       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.